Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01690299 · ClinicalTrials.gov registry record · Phase 3
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
A Phase 3 study of Psoriasis and Psoriatic Arthritis, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT01690299 is a Phase 3 study of Psoriasis and Psoriatic Arthritis that has completed, run by Amgen. The registered enrollment target is 250 participants, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT01690299, a Phase 3 study of Psoriasis and Psoriatic Arthritis, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will test the clinical effectiveness and safety of apremilast compared with placebo as well as etanercept compared with placebo in the same group of patients with moderate to severe plaque psoriasis.
Conditions Studied
Interventions
- DRUG Apremilast
- DRUG Placebo tablet
- DRUG Etanercept
- DRUG Placebo injection
Study Locations (20)
Florida
- Florida Center for Dermatology, PA - Jacksonville
- Florida Academic Dermatology Center - Miami
- International Dermatology Research - Miami
- Renstar Medical Research - Ocala
California
- Bakersfield Dermatology and Skin Cancer Medical Group - Bakersfield
- University of California Irvine-Department of Dermatology - Irvine
- University of California San Diego Medical Center - San Diego
Illinois
- NorthShore University HealthSystem - Skokie
- Southern Illinois University School of Medicine - Springfield
New York
- Forest Hills Dermatology Group - Forest Hills
- NYU Department of Dermatology - New York
Arizona
- Arizona Research Center - Phoenix
Colorado
- Horizons Clinical Research - Denver
District of Columbia
- George Washington University - Washington D.C.
Georgia
- Atlanta Dermatology, Vein and Research Center, PC - Alpharetta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2012-10-01 |
| Est. Completion | 2016-04-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01690299
The ClinicalTrials.gov registry entry for NCT01690299 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 125 other Psoriasis trials with a reported enrollment target (49% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Psoriasis appearing as the primary indexed condition, and to 4 interventions - of which Apremilast is the first listed.
NCT01690299 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT01690299 about?
NCT01690299 is a clinical study titled "Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis". This study will test the clinical effectiveness and safety of apremilast compared with placebo as well as etanercept compared with placebo in the same group of patients with moderate to severe plaque psoriasis.
What is the current status of trial NCT01690299?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2012-10-01. Estimated completion is 2016-04-04.
What conditions does trial NCT01690299 study?
This clinical trial studies the following conditions: Psoriasis, Psoriatic Arthritis.
What interventions are being tested in trial NCT01690299?
The interventions under investigation include: Apremilast (DRUG), Placebo tablet (DRUG), Etanercept (DRUG), Placebo injection (DRUG).
Who is sponsoring clinical trial NCT01690299?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01690299 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.